# A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

> **NCT02475161** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-42847922
- **DRUG:** Rabeprazole

## Key facts

- **NCT ID:** NCT02475161
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02475161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02475161, "A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02475161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*